The benefit of anthracyclines for patients with high 21-gene recurrence score (RS) is unclear, despite the widespread use of RS to guide adjuvant chemotherapy treatment for hormone receptor (HR)-positive /human epidermal growth factor receptor 2 (HER2)-negative breast cancer. This study aimed to assess whether patients with RS ≥ 31 would have improved outcomes with the addition of anthracyclines to taxane-based…
Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/HER2-negative breast cancer
Annals of Oncology | | N. Chen, J.Q. Freeman, S. Yarlagadda, A. Atmakuri, K. Kalinsky, L. Pusztai, J.A. Sparano, D. Huo, R. Nanda, F.M. Howard
Topics: breast-cancer, chemotherapy, research